Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.
see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.

Redox Pharmaceutical Corporation has patented a family of metallo-organic compounds with demonstrated effectiveness in antiviral, antibacterial and anti-inflammatory applications...